Literature DB >> 10724446

CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice.

M Takiguchi1, M Murakami, I Nakagawa, I Saito, A Hashimoto, T Uede.   

Abstract

MRL/MP-lpr/lpr (MRL/lpr) mice spontaneously develop an autoimmune syndrome closely resembling systemic lupus erythematosus (SLE) in humans, characterized by hypergammaglobulinemia, various autoantibody production, and the development of fatal glomerulonephritis. We have previously demonstrated that systemic administration of soluble form of CTLA4IgG prevented autoantibody-related diseases in MRL/lpr mice. To test the potential protective effects of CTLA4IgG gene delivery on the development of lupus nephritis, we injected MRL/lpr mice with a recombinant adenovirus vector containing CTLA4IgG gene, Adex1CACTLA4IgG (AdCTLA4IgG). It was demonstrated that a single administration of intravenous injection of AdCTLA4IgG into MRL/lpr mice resulted in almost complete amelioration of lupus nephritis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10724446     DOI： 10.1016/s0024-3205(99)00664-5

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  9 in total

Review 1.  New therapies and preventive strategies to treat and minimize damage in lupus.

Authors:  Henda Bouali; Gary Gilkeson
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

2.  Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat.

Authors:  T Honma; O Honmou; S Iihoshi; K Harada; K Houkin; H Hamada; J D Kocsis
Journal:  Exp Neurol       Date:  2005-06-20       Impact factor: 5.330

3.  Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat.

Authors:  Yoshifumi Horita; Osamu Honmou; Kuniaki Harada; Kiyohiro Houkin; Hirofumi Hamada; Jeffery D Kocsis
Journal:  J Neurosci Res       Date:  2006-11-15       Impact factor: 4.164

4.  Mesenchymal stem cells derived from peripheral blood protects against ischemia.

Authors:  Ryo Ukai; Osamu Honmou; Kuniaki Harada; Kiyohiro Houkin; Hirofumi Hamada; Jeffery D Kocsis
Journal:  J Neurotrauma       Date:  2007-03       Impact factor: 5.269

5.  Neuroprotection by PlGF gene-modified human mesenchymal stem cells after cerebral ischaemia.

Authors:  H Liu; O Honmou; K Harada; K Nakamura; K Houkin; H Hamada; J D Kocsis
Journal:  Brain       Date:  2006-08-10       Impact factor: 13.501

6.  I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat.

Authors:  T Nomura; O Honmou; K Harada; K Houkin; H Hamada; J D Kocsis
Journal:  Neuroscience       Date:  2005-10-17       Impact factor: 3.590

7.  Clinical manifestations and analyses of the cytotoxic T-lymphocyte associated-4 gene in two Japanese families with systemic lupus erythematosus.

Authors:  Keisuke Sugimoto; Shinsuke Fujita; Hidehiko Yanagida; Yoshihiro Shimada; Nobutada Tabata; Kazuro Yagi; Mitsuru Okada; Tsukasa Takemura
Journal:  Clin Exp Nephrol       Date:  2008-01-09       Impact factor: 2.801

Review 8.  Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2010-08-17

Review 9.  Gene therapy of the rheumatic diseases: 1998 to 2008.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.